Breast Cancer Imaging with Novel PET Tracers

David A Mankoff; Jean H Lee; William B Eubank

doi:10.1016/j.cpet.2009.10.003

Breast Cancer Imaging with Novel PET Tracers

PET Clin. 2009 Oct;4(4):371-80. doi: 10.1016/j.cpet.2009.10.003.

Authors

David A Mankoff¹, Jean H Lee², William B Eubank³

Affiliations

¹ Department of Radiology, University of Washington and Seattle Cancer Care Alliance, G2-600, 825 Eastlake Avenue East, Seattle, WA 98109, USA.
² Department of Radiology, University of Washington Medical Center, University of Washington and Seattle Cancer Care Alliance, Box 357115, Room BB308, 959 NE Pacific Street, Seattle, WA 98195, USA.
³ Department of Radiology (S-114-RAD), Puget Sound VA Health Care System, 1660 South Columbian Way, Seattle, WA 98108-1597, USA.

PMID: 27157306
DOI: 10.1016/j.cpet.2009.10.003

Abstract

Whereas (18)F-fluorodeoxyglucose (FDG)-PET/computed tomography has proven to be valuable for breast cancer diagnosis and response evaluation, it is likely that PET radiopharmaceuticals beyond FDG will contribute further to the understanding of breast cancer and thereby further direct breast cancer care. Increasingly specific and quantitative approaches will help direct treatment selection from an ever-expanding and increasing array of targeted breast cancer therapies. This article highlights 4 areas of ongoing research where preliminary patient results look promising: (1) tumor perfusion and angiogenesis, (2) drug delivery and transport, (3) tumor receptor imaging, and (4) early response evaluation. For each area, the biologic background is reviewed and early results are highlighted.